Percheron Therapeutics Ltd ATHJY:OTCPK

*Data is delayed | Exchange | USD
Last | 12/23/09 EDT
0.75UNCH (UNCH)
52 week range
0.75 - 0.75
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.75
  • 52 Week High0.75
  • 52 Week High Date12/23/09
  • 52 Week Low0.75
  • 52 Week Low Date12/23/09

Key Stats

  • Market Cap-
  • Shares Out45.08M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.75
  • 52 Week High0.75
  • 52 Week High Date12/23/09
  • 52 Week Low0.75
  • 52 Week Low Date12/23/09
  • Market Cap-
  • Shares Out45.08M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Percheron Therapeutics Ltd

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a...
Charmaine Gittleson M.D.
Non-Executive Independent Chairman of the Board
James Garner
Chief Executive Officer, Managing Director, Executive Director
Phillip Hains
Chief Financial Officer, Joint Company Secretary
Address
14 Wallace Avenue,, Toorak
Melbourne, VIC
3142
Australia